<a href="https://laohu8.com/S/CDXS">Codexis</a> posts Q3 revenue of $8.6 million with net loss of $19.6 million
Codexis Inc. reported total revenue of $8.6 million for the third quarter of 2025, compared to $12.8 million in the same period in 2024. Product gross margin improved to 64%, up from 61% the previous year. Research and development expenses were $13.9 million, while selling, general and administrative expenses totaled $11.2 million. The company reported a net loss of $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in the third quarter of 2024. Business highlights include a $37.8 million supply assurance agreement with Merck, expected to provide cash by the end of 2025, and a planned lease of a 34,000 square foot GMP facility. Codexis also noted continued commercial progress with 11 customers and 40 prospects in its pipeline. The company is reiterating its 2025 guidance and expects to issue 2026 guidance in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.